Αρχική World News OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced... World News OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma Από Ogkologos - 4 Αυγούστου, 2025 817 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Aromatase inhibitors cut breast cancer recurrence in younger patients 11 Φεβρουαρίου, 2022 The Pesticide Chemical Responsible For Mass Bee Die-Offs Is Killing Birds... 20 Αυγούστου, 2020 When Prenatal DNA Tests Point to Cancer 17 Μαΐου, 2023 FDA Approves Pembrolizumab for Advanced Oesophageal or Gastro-Oesophageal Carcinoma 30 Μαρτίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Tecartus Becomes First CAR T-Cell Therapy Approved for Adults with ALL ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC Longer PFS in Patients with Advanced Melanoma Treated with TILs than...
